Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of 15 Ordinary Shares by Mrs. K Thomson, a connected person to Director Mr. P C Thomson. This acquisition occurred on April 12, 2012, at a price of 1403.9264 pence per share, resulting from the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: April 12, 2012.
- Connected Person: Mrs. K Thomson (related to Director Mr. P C Thomson).
- Transaction Type: Acquisition of 15 Ordinary Shares via dividend reinvestment.
- Share Price: 1403.9264 pence per share.
- Notification Date: April 13, 2012.